Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy

What were the outcomes of patients who underwent retinal detachment (RD) repair while concomitantly using systemic mammalian target rapamycin (mTOR) inhibitor (MTI) therapy?In this cohort study, 681 patients who underwent RD repair with concomitant use of MTI therapy had a decreased risk of subsequent RD and need for further ocular intervention, including pars plana vitrectomy and complex RD repair compared with matched patients not using MTI therapy.These findings suggest that modulating mTOR and downstream signaling may present a therapeutic target for proliferative vitreoretinopathy prevention after primary RD repair; additional studies exploring the potential efficacy and safety of these agents in this setting should be considered.

Corresponding Author: Ehsan Rahimy, MD, Horngren Family Vitreoretinal Center, Department of Ophthalmology, Byers Eye Institute, Stanford University School of Medicine, 2452 Watson Ct, Palo Alto, CA 94303 (rahimye@stanford.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.